MAY 2, 2024
Invitation to the presentation of Orexo's Q1 2024 Interim Report
Key News
APRIL 26, 2024
Report from the Annual General Meeting
APRIL 17, 2024
Extended patent protection for OX640 in the US
ESG sustainable investing
Read all documents related to the refinancing of the existing bond - MARCH 2024
A commercial stage pharmaceutical company with three revenue generating pharmaceutical products
Development pipeline targeting large medical needs
AmorphOX® - a novel world leading nasal delivery technology leading to a new wave of products
To read all NEWS go to Media in the top menu
Key financial figures
Group net revenue
639 MSEK
Last Twelve Months, Q123-Q423
Group EBITDA
-32 MSEK
Last Twelve Months, Q123-Q423
US Pharma segment EBIT
283 MSEK
Last Twelve Months, Q123-Q423
Cash position
171 MSEK
Q423